NCT04876313View on ClinicalTrials.gov

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

PHASE2UnknownINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
DRUG

Nivolumab + Nab-paclitaxel

4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8

DRUG

Nivolumab

360 mg IV Q3W x 13 cycles

Trial Locations (1)

20132

RECRUITING

Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and Scientific Institute, Milan

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

IRCCS San Raffaele

OTHER

NCT04876313 - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) | Biotech Hunter | Biotech Hunter